<?xml version="1.0" encoding="UTF-8"?>
<p>Further to the ongoing PRAC safety review on Ibuprofen and Ketoprofen, EMA highlights the need for epidemiological studies to be conducted in a timely manner to provide adequate evidence on any effect of NSAIDs on disease prognosis for COVID-19. The Agency is reaching out to its stakeholders and is ready to actively support such studies, which could be useful in guiding any future treatment recommendations. EMA will provide further information as necessary and once the PRAC review is concluded (
 <xref rid="ref20" ref-type="bibr">20</xref>).
</p>
